The effect of oseltamivir on the disease progression of lethal influenza a virus infection: Plasma cytokine and miRNA responses in a mouse model

Disease Markers

Volumn 2016, Issue , 2016, Pages

  Chockalingam, Ashok K ^a   Hamed, Salaheldin ^a   Goodwin, David G ^b   Rosenzweig, Barry A ^a   Pang, Eric ^a   Boyne Ii, Michael T ^a   Patel, Vikram ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICRORNA; OSELTAMIVIR; TUMOR NECROSIS FACTOR ALPHA; ANTIVIRUS AGENT; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; INFLUENZA A; INFLUENZA A VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; BIOMARKERS, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; INFLUENZA A VIRUS; MICE; MICRORNAS; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84962415143     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2016/9296457     Document Type: Article

References (34)

1. K. Stohr, "Influenza-WHO cares, " The Lancet Infectious Diseases, vol. 2, no. 9, p. 517, 2002.
2. F. S. Dawood, A. D. Iuliano, C. Reed, et al., "Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study, " The Lancet Infectious Diseases, vol. 12, no. 9, pp. 687-695, 2012.
3. Z. X. Wong, J. E. Jones, G. P. Anderson, and R. C. Gualano, "Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung, " Influenza and Other Respiratory Viruses, vol. 5, no. 5, pp. 343-350, 2011.
4. R. W. Sidwell, K. W. Bailey, P. A. Bemis, M.-H. Wong, E. J. Eisenberg, and J. H. Huffman, "Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104, " Antiviral Chemistry & Chemotherapy, vol. 10, no. 4, pp. 187-193, 1999.
5. H.-L. Yen, A. S. Monto, R. G. Webster, and E. A. Govorkova, "Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice, " The Journal of Infectious Diseases, vol. 192, no. 4, pp. 665-672, 2005.
6. E. A. Govorkova, N. A. Ilyushina, J. L. McClaren, T. S. P. Naipospos, B. Douangngeun, and R. G. Webster, "Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mousemodel, " Antimicrobial Agents and Chemotherapy, vol. 53, no. 7, pp. 3088-3096, 2009.
7. T. Kuiken, B. Riteau, R. A. M. Fouchier, and G. F. Rimmelzwaan, "Pathogenesis of influenza virus infections: the good, the bad and the ugly, " Current Opinion in Virology, vol. 2, no. 3, pp. 276-286, 2012.
8. F. G. Hayden, R. S. Fritz, M. C. Lobo, W. G. Alvord, W. Strober, and S. E. Straus, "Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense, " The Journal of Clinical Investigation, vol. 101, no. 3, pp. 643-649, 1998.
9. R. T. Davey Jr., R. Lynfield, D. E. Dwyer, et al., "The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies, " PLoS ONE, vol. 8, no. 2, Article ID e57121, 2013.
10. Y. Kumar, C. Liang, G. V. Limmon, et al., "Molecular analysis of serum and bronchoalveolar lavage in a mouse model of influenza reveals markers of disease severity that can be clinically useful in humans, " PLoS ONE, vol. 9, no. 2, Article ID e86912, 2014.
11. J. Lv, D. Wang, Y.-H. Hua, et al., "Pulmonary immune responses to 2009 pandemic influenza A (H1N1) virus in mice, " BMC Infectious Diseases, vol. 14, article 197, 2014.
12. N. Lee, C. K. Wong, P. K. S. Chan, et al., "Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults, " PLoS ONE, vol. 6, no. 10, Article ID e26050, 2011.
13. M. D. de Jong, C. P. Simmons, T. T. Thanh, et al., "Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia, " Nature Medicine, vol. 12, no. 10, pp. 1203-1207, 2006.
14. S. G. Paquette, D. Banner, Z. Zhao, et al., "Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza a infection, " PLoS ONE, vol. 7, no. 6, Article ID e38214, 2012.
15. K. S. Tan, A. Armugam, S. Sepramaniam, et al., "Expression profile ofMicroRNAs in young stroke patients, " PLoS ONE, vol. 4, no. 11, Article ID e7689, 2009.
16. A. J. Tijsen, E. E. Creemers, P. D. Moerland, et al., "MiR423-5p as a circulating biomarker for heart failure, " Circulation Research, vol. 106, no. 6, pp. 1035-1039, 2010.
17. X. Chen, Y. Ba, L. Ma, et al., "Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases, " Cell Research, vol. 18, no. 10, pp. 997-1006, 2008.
18. L. Cui, Y. Qi, H. Li, et al., "Serum microRNA expression profile distinguishes enterovirus 71 and coxsackievirus 16 infections in patients with hand-foot-and-mouth disease, " PLoS ONE, vol. 6, no. 11, Article ID e27071, 2011.
19. S. Shrivastava, J. Petrone, R. Steele, G. M. Lauer, A. M. Di Bisceglie, and R. B. Ray, "Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression, " Hepatology, vol. 58, no. 3, pp. 863-871, 2013.
20. P. A. Tambyah, S. Sepramaniam, J. MohamedAli, et al., "microRNAs in circulation are altered in response to influenza A virus infection in humans, " PLoSONE, vol. 8, no. 10, Article IDe76811, 2013.
21. Z. Zhu, Y. Qi, A. Ge, et al., "Comprehensive characterization of serum microRNA profile in response to the emerging avian influenza A (H7N9) virus infection in humans, " Viruses, vol. 6, no. 4, pp. 1525-1539, 2014.
22. F. G. Hayden, J. J. Treanor, R. S. Fritz, et al., "Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment, "The Journal of theAmericanMedical Association, vol. 282, no. 13, pp. 1240-1246, 1999.
23. P. Ward, I. Small, J. Smith, P. Suter, and R. Dutkowski, "Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic, " The Journal of Antimicrobial Chemotherapy, vol. 55, supplement 1, pp. i5-i21, 2005.
24. A. J. Vogel, S. Harris, N. Marsteller, S. A. Condon, and D. M. Brown, "Early cytokine dysregulation and viral replication are associated with mortality during lethal influenza infection, " Viral Immunology, vol. 27, no. 5, pp. 214-224, 2014.
25. Y. M. Kang, B. M. Song, J. S. Lee, H. S. Kim, and S. H. Seo, "Pandemic H1N1 influenza virus causes a stronger inflammatory response than seasonal H1N1 influenza virus in ferrets, " Archives of Virology, vol. 156, no. 5, pp. 759-767, 2011.
26. C. K. P. Mok, H. H. Y. Lee, M. C. W. Chan, et al., "Pathogenicity of the novel A/H7N9 influenza virus in mice, " mBio, vol. 4, no. 4, 2013.
27. P. C. Reading, P. G. Whitney, D. L. Pickett, M. D. Tate, and A. G. Brooks, "Influenza viruses differ in ability to infect macrophages and to induce a local inflammatory response following intraperitoneal injection of mice, " Immunology and Cell Biology, vol. 88, no. 6, pp. 641-650, 2010.
28. J. Lv, Y. Hua, D. Wang, et al., "Kinetics of pulmonary immune cells, antibody responses and their correlations with the viral clearance of influenza A fatal infection in mice, " Virology Journal, vol. 11, no. 1, article no. 57, 2014.
29. H. Song, Q. Wang, Y. Guo, et al., "Microarray analysis of MicroRNA expression in peripheral blood mononuclear cells of critically ill patients with influenza A (H1N1), " BMC Infectious Diseases, vol. 13, no. 1, article 257, 2013.
30. Z. Wu, R. Hao, P. Li, et al., "MicroRNA expression profile of mouse lung infectedwith 2009 pandemic H1N1 influenza virus, " PLoS ONE, vol. 8, no. 9, Article ID e74190, 2013.
31. E. M. Vela, M. D. Kasoji, M. Q. Wendling, et al., "MicroRNA expression in mice infected with seasonal H1N1, swine H1N1 or highly pathogenic H5N1, " Journal of Medical Microbiology, vol. 63, no. 9, pp. 1131-1142, 2014.
32. Y. Li, E. Y. Chan, J. Li, et al., "MicroRNA expression and virulence in pandemic influenza virus-infected mice, " Journal of Virology, vol. 84, no. 6, pp. 3023-3032, 2010.
33. J. V. Rogers, J. A. Price, M. Q. S. Wendling, J. P. Long, and H. S. Bresler, "Preliminary microRNA analysis in lung tissue to identify potential therapeutic targets against H5N1 infection, " Viral Immunology, vol. 25, no. 1, pp. 3-11, 2012.
34. J. Louten, M. Beach, K. Palermino, M. Weeks, and G. Holenstein, "MicroRNAs expressed during viral infection: biomarker potential and therapeutic considerations, " Biomarker Insights, vol. 10, supplement 4, pp. 25-52, 2015.